Results of the phase III, randomized, double-blind GO-VIBRANT study show that patients with psoriatic arthritis (PsA) treated with intravenous golimumab 2 mg/kg (n = 241) had greater improvements in the signs and symptoms of the disease at week 14 and less radiographic progression at week 24 than those who received intraveous placebo (n = 239). 75.1% of those in the golimumab arm achieved ≥20% improvement according to ACR criteria (ACR20) at week 14, compared with 21.8% of the placebo group.
References
Kavanaugh, A. et al. Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week 24 of the GO-VIBRANT study. Arthritis Rheumatol. http://dx.doi.org/10.1002/art.40226 (2017)
Rights and permissions
About this article
Cite this article
Onuora, S. Intravenous golimumab effective for PsA. Nat Rev Rheumatol 13, 570 (2017). https://doi.org/10.1038/nrrheum.2017.157
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.157